GlassScriptPhysician profile
Tabitha A Shults
NPI 1144608605
$942.29
in general payments reported to CMS, 2019-2025
19 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $335 · 2023: $61.77 · 2024: $110 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $607.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $115.00 | 2021 | |
| Shionogi INC | $108.86 | 2024-2025 | Fetroja |
| Incyte Corporation | $99.99 | 2021 | |
| Abbvie INC. | $92.34 | 2024-2025 | |
| Coherus Oncology, INC. | $75.00 | 2021 | |
| Travere Therapeutics, INC. | $54.69 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $53.37 | 2024-2025 | Zerbaxa |
| Calliditas Therapeutics US INC. | $51.81 | 2023-2025 | Tarpeyo |
| Paratek Pharmaceuticals, INC. | $51.52 | 2025 | Nuzyra |
| La Jolla Pharmaceutical Company | $51.44 | 2024-2025 | Zevtera, Xerava |
| Insmed, INC. | $37.98 | 2025 | Arikayce |
| Viiv Healthcare Company | $28.02 | 2025 | Cabenuva |
| Aimmune Therapeutics, INC. | $25.39 | 2025 | Vowst |
| Tetraphase Pharmaceuticals, INC. | $20.85 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $15.86 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $15.73 | 2023 | Jynarque |
| Kite Pharma, INC. | $15.56 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $15.48 | 2025 | Onivyde |
| Seagen INC. | $13.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Shults listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.